var data={"title":"Imipenem and cilastatin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Imipenem and cilastatin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6359?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=imipenem-and-cilastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Imipenem and cilastatin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=imipenem-and-cilastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imipenem and cilastatin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182065\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Primaxin I.V.</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182066\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imipenem and Cilastatin for Injection;</li>\n      <li>Imipenem and Cilastatin for Injection, USP;</li>\n      <li>Primaxin;</li>\n      <li>RAN-Imipenem-Cilastatin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182088\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Carbapenem</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182068\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Doses based on <b>imipenem</b> content.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Susceptible bacterial species: </b>500 mg every 6 hours or 1,000 mg every 8 hours (maximum dose: 4,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intermediate susceptibility bacterial species:</b> 1,000 mg every 6 hours (maximum dose: 4,000 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Burkholderia pseudomallei</i></b> <b>(melioidosis) (off-label use):</b> IV: Initial: 20 mg/kg every 8 hours for at least 10 days (White 2003) <b>or</b> 25 mg/kg (up to 1 g) every 6 hours for at least 10 days (Currie 2003); continue parenteral therapy until clinical improvement then switch to oral therapy if tolerated and/or appropriate. Additional data may be necessary to further define the role of imipenem/cilastatin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intra-abdominal infections, complicated:</b> IV: 500 mg every 6 hours <b>or</b> 1 g every 8 hours for 4 to 7 days (provided source controlled). <b>Note:</b> Not recommended for mild to moderate, community-acquired intra-abdominal infections due to risk of toxicity and the development of resistant organisms (Solomkin 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neutropenic fever (off-label use):</b> IV: 500 mg every 6 hours (Paul 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nontuberculous mycobacterial disease (off-label use): </b> IV: <i>M. abscessus</i> skin, soft tissue, or bone infections: 500 mg every 6 to 12 hours; use in combination with other antibacterial agents (ATS/IDSA [Griffith 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, hospital acquired or ventilator-associated (off-label dose):</b> IV: 500 mg every 6 hours for 7 days; may consider shorter or longer duration depending on rate of clinical improvement. When used as empiric therapy, use in combination with an agent active against MRSA (unless coverage of MSSA only is appropriate) with or without an additional antipseudomonal agent (dependent on patient and institution-specific risk factors). <b> Note:</b> May need to decrease dose in patients weighing less than 70 kg to prevent seizures (Kalil 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and soft tissue necrotizing infections (off-label use):</b> IV: 1 g every 6 to 8 hours in combination with an agent effective against MRSA (eg, vancomycin, linezolid, daptomycin) for empiric therapy of polymicrobial [mixed] infections. Continue until further debridement is not necessary, patient has clinically improved, and patient is afebrile for 48 to 72 hours (IDSA [Stevens 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgical-site infection (intestinal or genitourinary tract surgery) (off-label use):</b> IV: 500 mg every 6 hours (IDSA [Stevens 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182081\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=imipenem-and-cilastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Imipenem and cilastatin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage based on <b>imipenem</b> content:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-CNS infections:</b> IV: Infants &ge;3 months, Children, and Adolescents: 15 to 25 mg/kg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum dosage: 4,000 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Burkholderia pseudomallei</i></b>\n      <b> (melioidosis) (off-label use):</b> IV: Initial: 20 mg/kg every 8 hours for at least 10 days (White 2003) <b>or</b> 25 mg/kg (up to 1 g) every 6 hours for at least 10 days (Currie 2003); continue parenteral therapy until clinical improvement, then switch to oral therapy if tolerated and/or appropriate. Additional data may be necessary to further define the role of imipenem/cilastatin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cystic fibrosis exacerbations:</b> IV: Infants, Children, and Adolescents: Up to 100 mg/kg/<b>day</b> divided every 6 hours (Strandvik 1988; Zobell 2012); maximum dose: 4 g daily has been used (Zobell 2012). <b>Note:</b> Efficacy in exacerbations may be limited due to rapid development of resistance (Zobell 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182069\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182070\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>\n        <i>Adults:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>US labeling</b> (estimation of renal function for the purpose of dosing adjustment should be done using the Cockcroft-Gault formula): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual dosing regimen of 500 mg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;90 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 to &lt;90 mL/minute: 400 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 to &lt;60 mL/minute: 300 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;15 to &lt;30 mL/minute: 200 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Do not administer imipenem and cilastatin unless hemodialysis is instituted within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual dosing regimen of 1,000 mg every 8 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;90 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 to &lt;90 mL/minute: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 to &lt;60 mL/minute: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;15 to &lt;30 mL/minute: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Do not administer imipenem and cilastatin unless hemodialysis is instituted within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Usual dosing regimen of 1,000 mg every 6 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;90 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;60 to &lt;90 mL/minute: 750 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 to &lt;60 mL/minute: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;15 to &lt;30 mL/minute: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;15 mL/minute: Do not administer imipenem and cilastatin unless hemodialysis is instituted within 48 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Canadian labeling: </b> Reduced IV dosage regimen based on creatinine clearance (mL/minute/1.73 m<sup>2</sup>) and body weight &ge;70 kg (<b>Note:</b> The manufacturer labeling recommends further proportionate dose reductions for patients &lt;70 kg, but does not provide specific dosing recommendations):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Mild renal impairment</i> (CrCl 31 to 70 mL/minute/1.73 m<sup>2</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fully susceptible organisms: Maximum dosage: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Less susceptible organisms (primarily some <i>Pseudomonas</i> strains): Maximum dosage: 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Moderate renal impairment</i> (CrCl 21 to 30 mL/minute/1.73 m<sup>2</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fully susceptible organisms: Maximum dosage: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Less susceptible organisms (primarily some <i>Pseudomonas</i> strains): Maximum dosage: 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Severe renal impairment</i> (CrCl 0 to 20 mL/minute/1.73 m<sup>2</sup>):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fully susceptible organisms: Maximum dosage: 250 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Less susceptible organisms (primarily some <i>Pseudomonas</i> strains): Maximum dosage: 500 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Patients with CrCl 6 to 20 mL/minute/1.73 m<sup>2</sup> should receive 250 mg every 12 hours or 3.5 mg/kg (whichever is lower) every 12 hours for most pathogens; seizure risk may increase with higher dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD): Use the dosing recommendation (for US labeling) for patients with a CrCl &ge;15 to &lt;30 mL/minute; administer dose after dialysis session and at intervals timed from the end of that dialysis session <b>or</b> 250 to 500 mg every 12 hours (Heintz 2009). <b>Note:</b> Dosing dependent on the assumption of 3 times/week, complete IHD sessions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous renal replacement therapy (CRRT) (Heintz 2009; Trotman 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1 to 2 L/hour and minimal residual renal function) and should not supersede clinical judgment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVH: Loading dose of 1 g followed by either 250 mg every 6 hours <b>or</b> 500 mg every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHD: Loading dose of 1 g followed by either 250 mg every 6 hours <b>or</b> 500 mg every 6 to 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CVVHDF: Loading dose of 1 g followed by either 250 mg every 6 hours <b>or</b> 500 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>Data suggest that 500 mg every 8 to 12 hours may provide sufficient time above MIC to cover organisms with MIC values &le;2 mg/L; however, a higher dose of 500 mg every 6 hours is recommended for resistant organisms (particularly <i>Pseudomonas</i> spp) with MIC &ge;4 mg/L or deep-seated infections (Fish 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5432719\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182043\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution: Imipenem 250 mg and cilastatin 250 mg; imipenem 500 mg and cilastatin 500 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Primaxin&reg; I.V.: Imipenem 250 mg and cilastatin 250 mg [contains sodium 18.8 mg (0.8 mEq)]; imipenem 500 mg and cilastatin 500 mg [contains sodium 37.5 mg (1.6 mEq)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182027\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182047\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV infusion only; do not administer IV push. Infuse doses &le;500 mg over 20 to 30 minutes; infuse doses &gt;500 mg over 40 to 60 minutes. If nausea and/or vomiting occur during administration, decrease the rate of IV infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182046\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial septicemia: </b>Treatment of septicemia caused by <i>Enterococcus faecalis, Staphylococcus aureus </i>(penicillinase-producing), <i>Escherichia coli, Klebsiella</i> species, <i>Pseudomonas aeruginosa,</i> <i>Serratia</i> species, <i>Enterobacter</i> species, <i>Bacteroides</i> species (including <i>Bacteroides fragilis</i>).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bone and joint infections: </b>Treatment of bone and joint infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>Staphylococcus epidermidis, Enterobacter</i> species, <i>P. aeruginosa.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis: </b>Treatment of endocarditis caused by<i> S. aureus</i> (penicillinase-producing).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gynecologic infections: </b>Treatment of gynecologic infections caused by <i>E. faecalis; S. aureus</i> (penicillinase-producing), <i>S. epidermidis, Streptococcus agalactiae</i> (group B streptococci), <i>E. coli</i>, <i>Klebsiella </i>species, <i>Proteus </i>species, <i>Enterobacter</i> species, <i>Bifidobacterium</i> species, <i>Bacteroides</i> species (including <i>B. fragilis), Gardnerella vaginalis</i>;<i> Peptococcus</i> species, <i>Peptostreptococcus</i> species, <i>Cutibacterium</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intra-abdominal infections: </b>Treatment of intra-abdominal infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>S. epidermidis, E. coli, Klebsiella</i> species, <i>Enterobacter</i> species, <i>Proteus</i> species, <i>Morganella morganii, P. aeruginosa, Citrobacter</i> species, <i>Clostridium</i> species, <i>Bacteroides</i> species (including <i>B. fragilis</i>), <i>Fusobacterium</i> species, <i>Peptococcus</i> species, <i>Peptostreptococcus</i> species, <i>Eubacterium</i> species, <i>Cutibacterium</i> species, <i>Bifidobacterium</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lower respiratory tract infections: </b>Treatment of lower respiratory tract infections caused by <i>S. aureus</i> (penicillinase-producing), <i>E. coli, Klebsiella</i> species, <i>Enterobacter</i> species, <i>Haemophilus influenzae, Haemophilus parainfluenzae, Acinetobacter</i> species, <i>Serratia marcescens</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections: </b>Treatment of skin and skin structure infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), S<i>. epidermidis, E. coli, Klebsiella</i> species, <i>Enterobacter species, Proteus vulgaris, Providencia rettgeri, M. morganii, P. aeruginosa, Serratia</i> species, <i>Citrobacter</i> species, <i>Acinetobacter</i> species, <i>Bacteroides</i> species (including <i>B. fragilis</i>), <i>Fusobacterium</i> species, <i>Peptococcus</i> species, <i>Peptostreptococcus</i> species.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urinary tract infections (complicated and uncomplicated): </b>Treatment of uncomplicated and complicated urinary tract infections caused by <i>E. faecalis, S. aureus</i> (penicillinase-producing), <i>E. coli, Klebsiella</i> species, <i>Enterobacter</i> species, <i>P. vulgaris, Providencia rettgeri, M. morganii, P. aeruginosa.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Limitations of use: Not indicated in patients with meningitis because safety and efficacy have not been established; not recommend in pediatric patients with CNS infections because of the risk of seizures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726672\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Burkholderia pseudomallei (melioidosis); Cystic fibrosis exacerbations (children and adolescents); Neutropenic fever; Nontuberculous mycobacterial disease; Skin and soft tissue necrotizing infections; Surgical-site infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182095\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imipenem may be confused with ertapenem, meropenem</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Primaxin may be confused with Premarin, Primacor</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182034\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Decreased hematocrit (infants and children 3 months to 12 years: 18%; neonates and infants &lt;3 months: 2%), decreased hemoglobin (infants and children 3 months to 12 years: 15%), eosinophilia (neonates, infants, and children to 12 years: 9% to 13%), thrombocythemia (infants and children 3 months to 12 years: 13%; neonates and infants &lt;3 months: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum AST (infants and children 3 months to 12 years: 18%; neonates and infants &lt;3 months: 6%), increased serum ALT (infants and children 3 months to 12 years: 11%; neonates and infants &lt;3 months: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Phlebitis (2% to 3%), tachycardia (neonates and infants &le;3 months: 2%; adults &lt;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Seizure (neonates and infants &le;3 months: 6%; adults &lt;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (&le;2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (neonates, infants, and children to 12 years: 3% to 4%; adults 2%), nausea (2%), oral candidiasis (neonates and infants &le;3 months: 2%), vomiting (&le;1% to 2%), gastroenteritis (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Proteinuria (infants and children 3 months to 12 years: 8%), urine discoloration (&le;1%), oliguria (neonates and infants &le;3 months: 2%; adults &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Neutropenia (infants and children 3 months to 12 years: 3%; adults &lt;1%), decreased platelet count (neonates and infants &lt;3 months: 2%), increased hematocrit (neonates and infants &lt;3 months: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum alkaline phosphatase (neonates and infants &lt;3 months: 3%), increased serum bilirubin (neonates and infants &lt;3 months: 3%), decreased serum bilirubin (neonates and infants &lt;3 months: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Irritation at injection site (infants, children, and adolescents 3 months to 16 years: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Increased serum creatinine (neonates and infants &lt;3 months: 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Abdominal pain, acute renal failure, agitation, agranulocytosis, anaphylaxis, angioedema, back pain (thoracic spinal), basophilia, bilirubinuria, bone marrow depression, brain disease, candidiasis, casts in urine, change in prothrombin time, chest discomfort, <i>Clostridium difficile</i> associated diarrhea, confusion, cyanosis, decreased serum sodium, dental discoloration, dizziness, drowsiness, drug fever, dysgeusia, dyskinesia, dyspnea, erythema at injection site, erythema multiforme, fever, flushing, glossitis, hallucination, headache, hearing loss, heartburn, hematuria, hemolytic anemia, hemorrhagic colitis, hepatic failure, hepatitis (including fulminant onset), hyperchloremia, hyperhidrosis, hypersensitivity, hyperventilation, hypotension, increased blood urea nitrogen, increased lactate dehydrogenase, increased monocytes, increased serum potassium, increased urinary urobilinogen, induration at injection site, injection site infection, jaundice, leukocytosis, leukocyturia, leukopenia, lymphocytosis, myoclonus, neutropenia, pain at injection site, palpitations, pancytopenia, paresthesia, polyarthralgia, polyuria, positive direct Coombs' test, pruritus, pruritus vulvae, pseudomembranous colitis, pseudomonas infection (resistant <i>P. aeruginosa</i>), psychiatric disturbances, sialorrhea, skin changes (texture), sore throat, Stevens-Johnson syndrome, thrombocytopenia, tinnitus, tongue changes (papillar hypertrophy), tongue discoloration, toxic epidermal necrolysis, tremor, urticaria, vertigo, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182050\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to imipenem/cilastatin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for carbapenems, penicillins, and cephalosporins is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182031\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: Carbapenems have been associated with CNS adverse effects, including confusional states and seizures (myoclonic); use caution with CNS disorders (eg, brain lesions and history of seizures) and adjust dose in renal impairment to avoid drug accumulation, which may increase seizure risk. However, there have been reports of adverse CNS effects in patients who had no recognized or documented underlying CNS disorder or compromised renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Serious hypersensitivity/anaphylactic reactions have been reported, including fatalities; may be more common in patients with a history of sensitivity to multiple allergens. Patients with a history of penicillin hypersensitivity may experience severe hypersensitivity reactions when treated with other beta-lactams; carefully inquire about previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams, and other allergens. Serious anaphylactic reactions require immediate discontinuation and supportive care as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required in patients with moderate to severe renal dysfunction. Increased seizure risk has been reported in patients with significant renal dysfunction. Do not use in patients with CrCl &le;15 mL/minute unless hemodialysis is instituted within 48 hours. For patients on hemodialysis, use is recommended only when the benefit outweighs the potential risk of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Valproic acid and derivatives: Carbapenems, including imipenem, may decrease the serum concentration of divalproex sodium/valproic acid increasing the risk of breakthrough seizures. Concurrent use of carbapenem antibiotics with divalproex sodium/valproic acid is generally not recommended. Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional antiseizure medication.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Additional potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Not recommended in pediatric CNS infections due to seizure potential. Not recommended in pediatric patients &lt;30 kg with impaired renal function (no data available).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299512\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182036\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8553&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the neurotoxic effect of Imipenem. Imipenem may decrease the serum concentration of CycloSPORINE (Systemic). Imipenem may increase the serum concentration of CycloSPORINE (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Imipenem. Specifically, the risk of seizures may be increased. Management: Avoid concomitant use of these agents unless the prospective benefits of therapy outweigh the risks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Imipenem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Carbapenems may decrease the serum concentration of Valproate Products.  Management: Concurrent use of carbapenem antibiotics with valproic acid is generally not recommended.  Alternative antimicrobial agents should be considered, but if a concurrent carbapenem is necessary, consider additional anti-seizure medication.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182039\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182052\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Due to pregnancy induced physiologic changes, some pharmacokinetic parameters of imipenem/cilastatin may be altered. Pregnant women have a larger volume of distribution resulting in lower serum peak levels than for the same dose in nonpregnant women. Clearance is also increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3878676\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Imipenem is excreted in human milk. The low concentrations and low oral bioavailability suggest minimal exposure risk to the infant. The US labeling recommends that caution be exercised when administering imipenem/cilastatin to breast-feeding women. The Canadian labeling recommends discontinuing breast-feeding if therapy is considered necessary. Nondose-related effects could include modification of bowel flora.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182053\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182041\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic renal, hepatic, and hematologic function tests; monitor for signs of anaphylaxis during first dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182030\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs); which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested. Cilastatin prevents renal metabolism of imipenem by competitive inhibition of dehydropeptidase along the brush border of the renal tubules.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182049\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Imipenem: ~20%; cilastatin: ~40%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Imipenem is metabolized in the kidney by dehydropeptidase I; cilastatin prevents imipenem metabolism by this enzyme.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Both drugs: Prolonged with renal impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: Imipenem: 1.7 to 2.4 hours; Cilastatin: 3.9 to 6.3 hours (Freij 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children: Imipenem: 1.2 hours (Blumer 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: ~60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Both drugs: Urine (~70% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323195\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Imipenem-Cilastatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (1): $5.99</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $11.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Primaxin IV Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-250 mg (1): $20.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-500 mg (1): $39.18</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182054\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anipen (PH);</li>\n      <li>Arzobema (MX);</li>\n      <li>Bacquire (ZW);</li>\n      <li>Bacqure (TH);</li>\n      <li>Bidinam (VN);</li>\n      <li>Bionam (TH);</li>\n      <li>Cilanem (JO);</li>\n      <li>Cilapenem (KR, TH);</li>\n      <li>Cispenam (BD);</li>\n      <li>Haizheng Junte (CN);</li>\n      <li>Imenam (TW);</li>\n      <li>Imicila Alvogen (TH);</li>\n      <li>Imiclast (ID);</li>\n      <li>Iminem (BD);</li>\n      <li>Iminen (MX);</li>\n      <li>Imipen (PH);</li>\n      <li>Imivex (PH);</li>\n      <li>Inem (BD, CL, PY);</li>\n      <li>Minem (TH);</li>\n      <li>Nemcis (VN);</li>\n      <li>Nimedine (MT);</li>\n      <li>Pelascap (ID);</li>\n      <li>Pelastin IV (ID);</li>\n      <li>Penam (PH);</li>\n      <li>Plastin (PH);</li>\n      <li>Premax (JO);</li>\n      <li>Prepenem (HK, KR, PH, TH);</li>\n      <li>Primax (BD);</li>\n      <li>Primaxin (AU, GB, GR, MT, NZ);</li>\n      <li>Primaxin IV (BB, BM, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Sianem (TH);</li>\n      <li>Supernem (TW);</li>\n      <li>Supranem (UA);</li>\n      <li>Talispenem (VN);</li>\n      <li>Tenacid (IT);</li>\n      <li>Tiaktam (UA);</li>\n      <li>Tienam (AE, BD, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DK, DO, EC, EE, EG, ES, ET, FI, FR, GT, HK, HN, HR, ID, IE, IL, IN, IT, JO, JP, KW, LB, LT, LU, LV, MX, MY, NI, NL, NO, PA, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SG, SK, SV, TH, TR, TW, VN);</li>\n      <li>Tiesilan (CO, EC);</li>\n      <li>Timipen (ID);</li>\n      <li>Tipem (KR);</li>\n      <li>Tiyenam (UA);</li>\n      <li>Vexpinem (PH);</li>\n      <li>Xerxes (ID);</li>\n      <li>Zienam (AR, AT, DE, PY, UY, VE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahonkhai VI, Cyhan GM, Wilson SE, et al, &ldquo;Imipenem-Cilastatin in Pediatric Patients: An Overview of Safety and Efficacy in Studies Conducted in the United States,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(11):740-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2687787/pubmed\" target=\"_blank\" id=\"2687787\">2687787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balfour JA, Bryson HM, and Brogden RN, &ldquo;Imipenem/Cilastatin: An Update of Its Antibacterial Activity, Pharmacokinetics, and Therapeutic Efficacy in the Treatment of Serious Infections,&rdquo; <i>Drugs</i>, 1996, 51(1):99-136.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/8741235/pubmed\" target=\"_blank\" id=\"8741235\">8741235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer JL, &quot;Pharmacokinetic Determinants of Carbapenem Therapy in Neonates and Children,&quot; <i>Pediatr Infect Dis J</i>, 1996, 15(8):733-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/8858691/pubmed\" target=\"_blank\" id=\"8858691\">8858691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bomback T, Sesin GP, and Mucciardi N, &ldquo;Possible Imipenem/Cilastatin-Induced Aplastic Anemia,&rdquo; <i>Pharm Therapeut</i>, 1995, 20(5):293-302.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chung AM, Reed MD, and Blumer JL, &ldquo;Antibiotics and Breast-Feeding: A Critical Review of the Literature,&rdquo; <i>Paediatr Drugs</i>, 2002, 4(12):817-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/12431134/pubmed\" target=\"_blank\" id=\"12431134\">12431134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Currie BJ, &quot;Melioidosis: An Important Cause of Pneumonia in Residents of and Travellers Returned from Endemic Regions,&quot; <i>Eur Respir J</i>, 2003, 22(3):542-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/14516149/pubmed\" target=\"_blank\" id=\"14516149\">14516149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Finch RG, Craddock C, Kelly J, et al, &ldquo;Pharmacokinetic Studies of Imipenem/Cilastatin in Elderly Patients,&rdquo; <i>J Antimicrob Chemother</i>, 1986, 18(Suppl E):103-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fish DN, Teitelbaum I, and Abraham E, &quot;Pharmacokinetics and Pharmacodynamics of Imipenem During Continuous Renal Replacement Therapy in Critically Ill Patients,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(6):2421-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/15917542/pubmed\" target=\"_blank\" id=\"15917542\">15917542</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/21258094/pubmed\" target=\"_blank\" id=\"21258094\">21258094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freij BJ, McCracken GH Jr, Olsen KD, et al, &quot;Pharmacokinetics of Imipenem-Cilastatin in Neonates,&quot; <i>Antimicrob Agents Chemother</i>, 1985, 27(4):431-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3859242/pubmed\" target=\"_blank\" id=\"3859242\">3859242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. <i>Am J Respir Crit Care Med</i>. 2007;175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19072244\"></a>High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;48(2):149-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19072244/pubmed\" target=\"_blank\" id=\"19072244\">19072244</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society [published online July 14, 2016]. <i>Clin Infect Dis</i>. doi: 10.1093/cid/ciw353.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/27418577/pubmed\" target=\"_blank\" id=\"27418577\">27418577</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leo RJ and Ballow CH, &ldquo;Seizure Activity Associated With Imipenem Use: Clinical Case Reports and Review of the Literature,&rdquo; <i>DICP</i>, 1991, 25(4):351-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/1926901/pubmed\" target=\"_blank\" id=\"1926901\">1926901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Cornia PB, et al, &quot;2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22619242/pubmed\" target=\"_blank\" id=\"22619242\">22619242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norrby SR, &ldquo;Carbapenems,&rdquo; <i>Med Clin North Am</i>, 1995, 79(4):745-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/7791421/pubmed\" target=\"_blank\" id=\"7791421\">7791421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Donovan CA, White ML, Cheung A, et al, &ldquo;Seizure Incidence With Imipenem Use at VA Hospital,&rdquo; <i>Hosp Formul</i>, 1995, 30:172-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Overturf GD, &ldquo;Use of Imipenem-Cilastatin in Pediatrics,&rdquo; <i>Pediatr Infect Dis J</i>, 1989, 8(11):792-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2687788/pubmed\" target=\"_blank\" id=\"2687788\">2687788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16344285\"></a>Paul M, Yahav D, Fraser A, et al, &ldquo;Empirical Antibiotic Monotherapy for Febrile Neutropenia: Systematic Review and Meta-Analysis of Randomized Controlled Trials,&rdquo; <i>J Antimicrob Chemother</i>, 2006, 57(2):176-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/16344285/pubmed\" target=\"_blank\" id=\"16344285\">16344285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Primaxin (imipenem and cilastatin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Primaxin (imipenem and cilastatin) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10476746\"></a>Simpson AJH, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. <i>Clin Infect Dis</i>. 1999;29(2):381-387.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/10476746/pubmed\" target=\"_blank\" id=\"10476746\">10476746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solomkin JS, Mazuski JE, Bradley JS, et al, &ldquo;Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20034345/pubmed\" target=\"_blank\" id=\"20034345\">20034345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Somani P, Freimer EH, Gross ML, et al, &ldquo;Pharmacokinetics of Imipenem-Cilastatin in Patients With Renal Insufficiency Undergoing Continuous Ambulatory Peritoneal Dialysis,&rdquo; <i>Antimicrob Agents Chemother</i>, 1988, 32(4):530-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3377464/pubmed\" target=\"_blank\" id=\"3377464\">3377464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):e10-e52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/24973422/pubmed\" target=\"_blank\" id=\"24973422\">24973422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3132441\"></a>Strandvik B, Malmborg AS, Bergan T, Michalsen H, Storr&oslash;sten OT, Wretlind B. Imipenem/cilastatin, an alternative treatment of pseudomonas infection in cystic fibrosis. <i>J Antimicrob Chemother</i>. 1988;21(4):471-480.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3132441/pubmed\" target=\"_blank\" id=\"3132441\">3132441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tegeder I, Bremer F, Oelkers R, et al, &ldquo;Pharmacokinetics of Imipenem-Cilastatin in Critically Ill Patients Undergoing continuous Veno-Venous Hemofiltration,&rdquo; <i>Antimicrob Agents Chemother</i>, 1997, 41(12):2640-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/9420033/pubmed\" target=\"_blank\" id=\"9420033\">9420033</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41(8):1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toon S, Hopkins KJ, Garstang FM, et al, &ldquo;Pharmacokinetics of Imipenem and Cilastatin After Their Simultaneous Administration to the Elderly,&rdquo; <i>Br J Clin Pharmacol</i>, 1987, 23(2):143-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/3470047/pubmed\" target=\"_blank\" id=\"3470047\">3470047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20835502\"></a>Ulug M, Gedik E, Girgin S, et al, &ldquo;Pyogenic Liver Abscess Caused By Community-Acquired Multidrug Resistance <i>Pseudomonas aeruginosa</i>,&rdquo; <i>Braz J Infect Dis</i>, 2010, 14(3):218.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/20835502/pubmed\" target=\"_blank\" id=\"20835502\">20835502</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White NJ, &ldquo;Melioidosis,&rdquo; <i>Lancet</i>, 2003, 361(9370):1715-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/12767750/pubmed\" target=\"_blank\" id=\"12767750\">12767750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong VK, Wright HT Jr, Ross LA, et al, &ldquo;Imipenem/Cilastatin Treatment of Bacterial Meningitis in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1991, 10(2):122-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2062603/pubmed\" target=\"_blank\" id=\"2062603\">2062603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhanel GG, Ketter N, Rubinstein E, et al, &ldquo;Overview of Seizure-Inducing Potential of Doripenem,&rdquo; <i>Drug Safety</i>, 2009, 32(9):709-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/19670912/pubmed\" target=\"_blank\" id=\"19670912\">19670912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhanel GG, Wiebe R, Dilay L, et al, &ldquo;Comparative Review of the Carbapenems,&rdquo; <i>Drugs</i>, 2007, 67(7):1027-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/17488146/pubmed\" target=\"_blank\" id=\"17488146\">17488146</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22911974\"></a>Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. <i>Pediatr Pulmonol</i>. 2012;47(12):1147-1158.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/imipenem-and-cilastatin-drug-information/abstract-text/22911974/pubmed\" target=\"_blank\" id=\"22911974\">22911974</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8553 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182065\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182066\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F182088\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F182068\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F182081\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F182069\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F182070\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5432719\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182043\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F182027\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F182047\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F182046\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726672\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182095\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182034\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182050\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182031\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299512\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182036\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F182039\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F182052\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3878676\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F182053\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F182041\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182030\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F182049\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323195\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182054\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8553|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=imipenem-and-cilastatin-patient-drug-information\" class=\"drug drug_patient\">Imipenem and cilastatin: Patient drug information</a></li><li><a href=\"topic.htm?path=imipenem-and-cilastatin-pediatric-drug-information\" class=\"drug drug_pediatric\">Imipenem and cilastatin: Pediatric drug information</a></li></ul></div></div>","javascript":null}